Home Search

immunotherapy - search results

If you're not happy with the results, please do another search
Woman donating blood

Biocept, UCSD Med Center Partner on Clinical Validation Study for PD-L1 Assay in NSCLC

Biocept and University of California San Diego (UCSD) Medical Center will assess the company’s Target Selector assay in NSCLC patients
Source: Meletios Verras/Getty Images

CRISPR/Cas9 Can Create Killer T Cells Highly Sensitive to Cancer Cell Antigens

The engineered killer T cells are 1,000 times more sensitive to cancer cell antigens to allow much better targeting to cancer cell lines
The Leukemia & Lymphoma Society® (LLS) has committed an additional $46 million to institutions worldwide toward research into various blood cancers

Leukemia & Lymphoma Society Awards $46M in Research Grants

The new funding increases to 254 the number of active LLS grants and features 23 in precision medicine and 17 in immunotherapy projects
Source: Julio C. Valencia

March of the Microbes

Researchers are harnessing the power of the human microbiome to improve health and target disease
Memorial Sloan Kettering Cancer Center has won FDA authorization for MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) assay

MSK’s Approved NGS-Based Tumor Panel Leads to FDA Assay Review Pathway

Memorial Sloan Kettering Cancer Center wins FDA authorization for MSK-IMPACT assay, the first tumor-profiling LDT to win agency approval
At the Personalized Medicine Conference in Boston

Illumina’s Flatley Describes the “Shock and Awe” of Personalized Medicine at PMC

Flatley receives Personalized Medicine Coalition's Lifetime Achievement Award and uses occasion to detail his views on personalized medicine
Epic Sciences has added simultaneous microsatellite instability and chromosomal instability analyses to its cancer immunotherapy NGS workflowfor clinical research of cancer immunotherapies. [Source: Rita Elena Serda

Epic Sciences Adds Analyses to Enhance Patient Selection for Cancer Immunotherapies

Epic Sciences adds simultaneous microsatellite instability and chromosomal instability analyses to its cancer immunotherapy NGS workflow

Gut Microbiome Makeup Instrumental in Response to Anti-PD-1 Therapy for Melanoma

A probiotic regimen to alter the gut microbiome could be beneficial for patients receiving anti-PD-1 immunotherapy for melanoma
IsoPlexis' has won a two-year

IsoPlexis Wins $1.8M NCI SBIR Grant toward Platform to Assess CAR-T Therapies

IsoPlexis has won a $1.8 million NCI SBIR grant to develop a platform designed to help predict patient response to CAR-T cell therapies
MedGenome has raised $30M in Series C financing toward advancing biomarker discovery programs and its OncoPept™ cancer immunotherapy biomarker solutions. [Source: 3desc/Fotolia]

MedGenome Completes $30M Series C Financing

MedGenome has raised $30M in Series C financing toward biomarker discovery programs and OncoPept cancer immunotherapy biomarker solutions


Inside Precision Medicine